双介入治疗延长肝癌患者的总生存期  

Prolong overall survival rate for patients with liver cancer receiving double interventional therapy

作　　者：李凌[1] 史芳[1] 冯龙[1] 吴建兵[1] 郭武华[1] 蒋为民[1] 

机构地区：[1]南昌大学第二附属医院肿瘤科,330006

出　　处：《实用医学杂志》2010年第5期764-766,共3页The Journal of Practical Medicine

基　　金：江西省科技厅课题(编号:20041B0303100)

摘　　要：目的:探讨双介入治疗对延长肝癌患者总生存期的作用。方法:对36例肝癌患者(治疗组)在经皮导管肝动脉化疗栓塞(TACE)治疗后再经皮穿刺门静脉置管时辰化疗,并与36例对照组患者进行比较。结果:治疗组与对照组甲胎蛋白值及肝癌瘤体大小的变化经统计学分析两组之间差异无显著性;两组1、2、3、5年生存率分别为52.78%、38.01%、30.09%和30.09% vs 33.33%、19.12%、11.17%和11.17%;中位生存期为14.00个月 vs 10.33个月,两组的总生存期差异有显著性。结论:门静脉置管时辰化疗联合TACE双介入治疗中晚期肝癌的近期疗效并无明显差异,但可以明显延长肝癌患者的总生存期。Objective To explore the effect of double interventional therapy on overall survival rate for patients with liver cancer. Methods After TACE treatment, 36 patients with advanced liver cancer received pureutaneous portal vein ehronomodulated chemotherapy. The effect on the survival rate was compared between these patients and 36 controlled subjects. Results There were no significant differences between the two groups in the changes in AFP level and tumor size; however, the overall survival rate differed significantly （52.78% vs. 33.33% for for 1-year suvival, 38.01% vs. 19.12% for 2-year survival, 30.09% vs. 11.17% for 3-year survival, and 30.09% vs. 11.17% for 5-year survival; 14.00 months vs. 10.33 months for median survival）. Conclusions Double interventional therapy combined with portal vein chronomodulated chemotherapy has no effect on the short-term efficacy for patients with advanced liver cancer, but it can markedly prolong the overall survival rate.

关 键 词：肝肿瘤 双介入 总生存期 

分 类 号：R735.7[医药卫生—肿瘤]